How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

AIDS

Volumn 23, Issue 17, 2009, Pages 2237-2245

  Hill, Andrew ^a   Van Der Lugt, Jasper ^b   Sawyer, Will ^c   Boffito, Marta ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c MetaVirology Ltd   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Amprenavir; Atazanavir; Clinical pharmacology; Darunavir; Fosamprenavir; Indinavir; Lopinavir; Ritonavir; Saquinavir

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ELVITEGRAVIR; GS 9350; INDINAVIR; INDINAVIR PLUS RITONAVIR; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MELTREX; MIDAZOLAM; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MEDLINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HUMANS; PYRIMIDINONES; RITONAVIR; TREATMENT OUTCOME;

EID: 70449440262     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328332c3a5     Document Type: Review

References (50)

1. Cameron D, Heath-Chiossi M, Danner S, Cohen C, Kravick S, Maurath C, et al. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351:543-549.
2. Markowitz M, Saag M, Powderly W, Hurley A, Hsu A, Valdes J, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333:1534-1539.
3. Danner S, Carr A, Leonard J, Lehman L, Gudiol F, Gonzalez J, et al. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333:1528-1533.
4. Hsu A, Granneman R, Bertz R. Ritonavir, clinical pharmaco-kinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35:275-291.
5. Hammer S, Eron J, Reiss P, SchooleyR, Thompson M, Walmsley S, et al. Antiretroviral treatment of Adult HIV infection. 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
6. Klein C, Chiu Y, Awni W, Ng J, Xiong J, Roth W, et al. A pivotal biostudy comparing ritonavir 100 mg film coated tablet to a ritonavir soft-gelatin capsule in healthy adult subjects [abstract THAB404]. World AIDS Conference; August 2008; Mexico City, Mexico.
7. Klein C, Chiu Y, Awni W, Ng J, Cui Y, Morris J, et al. The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film coated tablet in healthy adult subjects [abstract P247]. 9th International Workshop on Clinical Pharmacology of HIV therapy; April 2008; New Orleans, USA.
8. Shafran S, Mashinter L, Roberts S. Effects of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6:421-426.
9. Boffito M, Collot-Teixeira S, De Lorenzo F, Waters L, Fletcher C, Back D, et al. Plasma exposure of 100mg once and twice daily decreases HDL and CD36 expression but only twice daily dosing increases triglycerides: potential effect of ritonavir on cardiovascular disease [abstract 930]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA, USA.
10. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleo-side analogues, efavirenz and ritonavir boosted protease inhibitors on lipid levels. HIV Clin Trials 2009; 10:1-12.
11. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev 2009; 11:8-30.
12. Mathias A, Lee M, Callebut C, Xu L, Tsai L, Murray B, et al. GS-9350: a pharmacoenhancer without anti-HIV activity [abstract 40]. 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal, Canada.
13. Gulnick S, Eissenstat M, Afonina E, Ludkte D, Erikson J, Dagger R, et al. Preclinical and early clinical evaluation of SPI-452, a new pharmacokinetic enhancer [abstract 41]. 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal, Canada.
14. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir pharmaco-kinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharamacol 2001; 52:255-264.
15. Kilby J, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002; 3:97-104.
16. van der Lugt J, Gorowara M, Avihingsanon A, Burger D, Ana-nworanich J, Sringam K, et al. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. AIDS 2009; 23:1176-1179.
17. Kurowski M, Staszewski S, Arslan A, Nagaraja N, Derendorf H, Stark T, et al. Influence of 50mg, 100mg and 200mg ritonavir (RTV) on the pharmacokinetics (PK) of amprenavir (APV) after multipledosesinhealthyvolunteersforoncedaily(OD) andtwice daily (BID) regimens [abstract 351]. 1st IAS Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires, Argentina.
18. Sadler B, Piliero P, Preston S, Lloyd P, Lou Y, Stein D. Pharma-cokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001; 15:1009-1018.
19. Ruane P, Luber A, Wire M, Lou Y, Shalton M, Lancaster C, Pappa K. Plasma amprenavir pharmacokinetics and tolerability following administration of 1400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 2007; 51:560-565.
20. Taburet A, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, et al. Interactions between amprenavir and the lopinavir-rito-navir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004; 75:310-323. (Pubitemid 38471556)
21. Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, et al. Steady-state pharmacokinetics of saquinavir hard-gel/ ritonavir/fosamprenavir in HIV-1 infected patients. J Acquir Immune Defic Syndr 2004; 37:1376-1384.
22. Hoetelmans R, van der Sandt I, De Pauw M, Struble K, Peeters M, van der Geest R. TMC114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers [abstract and poster 549]. 10th Conference on Retroviruses and Opportunistic Infections; 10-14 February 2003; Boston, USA.
23. Alexander C, Harris M, Joy R. Effect on atazanavir (ATV) and ritonavir (rtv) plasma levels of increasing ATV/rtv daily dosing from 300/100mg to 300/200mg and 400/200mg [abstract 91; poster 8.3]. 6th Intl Workshop on Clinical Pharmacology of HIV Therapy; 28-30 April 2005; Québec.
24. Saah A, Winchell G, Nessly M, Seniuk M, Rhodes R, Deutsch P. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Che-mother 2001; 45:2710-2715.
25. McCallister S, Sabo J, Mayers D, Galitz L. An open-label, steady-state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal, healthy volunteers (BI 1182.5) [abstract 343W]. 9th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, USA.
26. Flexner C, Chiu Y-L, Foit C, Perez P, Tillmann E, Podzdamczer D, et al. Steady-state pharmacokinetics and short-term virolo-gic response to two lopinavir-ritonavir (LPV/r) high-dose regimens in multiple antiretroviral experienced subjects (study 049) [abstract 843]. Second IAS Conference on HIV Pathogen-esis and Treatment; July 2003; Paris France.
27. Murphy R, Brun S, Hicks C, Eron J, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-näive adults with HIV-1 infection: 48 week results. AIDS 2001; 15:1-9.
28. Lal R, Hsu A, Granneman G, El-Shourbagy T, Johnson M, Lam W, et al. Multiple dose safety, tolerability and pharmacoki-netics of ABT-378 in combination with ritonavir [abstract I-194]. 5th CROI; February 1998; Chicago, USA.
29. van der Lugt J, Autar RS, Ubolyam S, Garcia E, Sankote J, Avihingson A, et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 2008; 61:1145-1153.
30. Hsu A, Granneman R, Guoliang C, Carothers L, El-Shourbagy T, Baroldi P, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63:453-464.
31. Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, Miralles D. Effects of ritonavir-boosted dar-unavir vs. ritonavir boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 2009; 10:318-327
32. Merck 2005: Crixivan (indinavir sulphate) capsules. FDA product information
33. BaldwinJ,BorinM,FerryJ.Pharmacokinetic interaction between the HIV protease inhibitors tipranavir and ritonavir [abstract 657]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco, USA.
34. Stephan C, v Hentig N, Kourbeti I, Dauer B, Mosch M, Lutz T, et al. Saquinavir exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18:503-508.
35. Merry C, Barry M, Mulcahy F, Ryan M, Heavey J, Tjia J, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11:F29-F33. (Pubitemid 27112999)
36. Cameron W, Japour A, Xu Y, Hsu A, Mellors J, Farthing C, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13:213-224.
37. Kilby J, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus mini-dose ritonavir in HIV-negative adults. Antimicrob Agents Chemother 2000; 44:2672-2678.
38. Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, et al. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100mg once daily versus twice daily. J Antimicrob Agents Chemother 2005; 55:542-545
39. BoffitoM,MirallesD,HillA.Pharmacokinetics,efficacyandsafety of darunavir/ritonavir 800/100mgonce-dailyintreatment-näive and experienced patients. HIV Clin Trials 2008; 9:418-427.
40. Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A. Absorption, metabolism and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos 2009; 37:1521-1529.
41. Bristol-Myers Squibb Company. Reyataz (atazanavir sulphate) capsules. Product information. www.reyataz.com.
42. BoffitoM,KurowskiM,KruseG, HillA,BenzieA,NelsonM,etal. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18:1291-1297.
43. Klein C, Chiu Y, Awni W, Zhu T, Heuser R, Doan T, et al. The tablet formulation of lopinavir/ritonavir provides similar bioa-vailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Ac-quir Immune Defic Syndr 2007; 44:401-410.
44. Sham HL, Kempf D, Molla A, Marsh K, Kumar G, Chen C, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42:3218-3224.
45. Meynard J, Lacombe K, Poirier J, Masseguin C, Lefebvre B, Slama L, et al. Virological efficacy and impact on lipids profile of a reduced dosing (2 tablets BID) of lopinavir/ritonavir (LPV/ r) in HIV infected patients (Kaledose Trial) [abstract H-1384]. 46th ICAAC; September 2006; San Francisco, USA.
46. Klein C, Xiong J, Ng J, Causemaker S, Li J, Chiu Y, et al. Comparison of lopinavir and ritonavir tablet and soft gelatin capsule pharmacokinetics in antiretroviral-naïve HIV-1 infected subjects [abstract P37]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 2008; New Orleans, USA.
47. Autar RS, Wit FW, Sankote J, Sutthichom D, Kimenai E, Hassink E. Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. AIDS 2007; 21:1535-1539.
48. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
49. Gonzalez de Requena D, Blanco F, Garcia-Benayas T. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care 2003; 17:443-445.
50. Guiterrez F, Padilla S, Navarro A, Masia M, Hernandez I, Ramos J, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir containing regimens. J Acquir Immune Defic Syndr 2003; 33:594-600